Saturday 17 October 2026
Export RNXT’s income statement to Excel — free account
RenovoRx, Inc.
RNXT Healthcare Biotechnology
RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024. In the quarter to June 2026, revenue grew 115.4%, EPS grew 25.0% and free cash flow fell 27.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.15
0.04
−3.36%
Follow RNXT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 4.67 | 1.50 | 0.53 | 0.77 | 0.70 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 16.74 | 5.11 | 5.75 | 2.12 | 1.69 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 8 | 6 | 9 | 8 | 10 | 17 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 1 | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | 100.00 | 70.88 | |||||
| EBT | — | — | — | (4) | (4) | (6) | (10) | (10) | (9) | (11) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (20,497.67) | (994.48) | |||||
| Net income | — | 0 | — | (4) | (4) | (6) | (10) | (10) | (9) | (11) | |||||
| Depreciation | — | — | — | — | 0 | 1 | 0 | — | — | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | ||||
| Earnings | — | — | — | (1.76) | (1.72) | (1.21) | (1.09) | (0.99) | (0.40) | (0.32) | |||||
| Cash flow | — | — | — | (1.54) | (1.59) | (1.13) | (0.97) | (1.00) | (0.41) | (0.31) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (1.54) | (1.59) | (1.14) | (0.97) | (1.00) | (0.41) | (0.31) | |||||
| Book value | — | — | — | (5.02) | (6.62) | 2.94 | 0.68 | (0.29) | 0.20 | 0.15 | |||||
| Shares, m | — | — | — | 2 | 2 | 5 | 9 | 10 | 22 | 35 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 26.43 | |||||
| P/B | — | — | — | — | — | — | — | — | 6.42 | 5.47 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 24.45 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (2.88) | (2.50) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (4) | (6) | (9) | (10) | (9) | (11) | ||||
| Capex | — | — | — | — | — | 0 | — | — | 0 | 0 | |||||
| Free cash flow | — | — | — | (3) | (4) | (6) | (9) | (10) | (9) | (11) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | (2) | 15 | 6 | 0 | 6 | 6 | ||||
| Total debt | — | — | — | 12 | 3 | — | — | — | — | — | |||||
| Net debt | — | — | — | 10 | 1 | (15) | (6) | (1) | (7) | (7) | |||||
| Shareholders’ equity | — | — | — | (11) | (15) | 15 | 6 | — | 4 | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (338.24) | (181.55) | (69.49) | (83.98) | (234.38) | (183.93) | (137.77) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (2,257.56) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 30.01 | 29.69 | (1,825.11) | (91.94) | (646.98) | (1,192.69) | (225.62) | |||||
Negative figures in brackets.
value withheld pending a data check
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
RenovoRx, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TENX Tenax Therapeutics, Inc. | $56.5M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GUTS Fractyl Health, Inc. | $55.2M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +115.40% (above 0%: growing) | n/m | −27.63% (below 0%: shrinking) | 84.27% | (368.43%) | |
| BOLD Boundless Bio, Inc. | $53.5M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $52.0M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | Compare |
| Median of peers | $54.8M | — | — | −57.14% | — | −55.76% | 50.00% | 0.00% |
RenovoRx, Inc. (RNXT) key facts
- Concern: RenovoRx, Inc. reported a net loss of $11.2 million, or a loss of $0.32 per share, for fiscal 2025.
- Strength: RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024.
- RenovoRx, Inc. (RNXT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, RNXT traded at $1.15, a market capitalization of $53.7 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 27.5× sales.
- Return on equity was −225.6% and debt-to-equity 0.00.
- Its Altman Z-score is −8.04 (distress zone) for fiscal 2025.